RxDoctor Payments Data

Benjamin Perry, DO

Dermatology · Meridian, IDNPI 1710325758

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,354 of the $3,780 with a category attached, or 88.7%. 26 manufacturers reported payments, led by AbbVie at 25.0% of the total.

$3,780in general payments, 2019–2025

Across 191 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$943
  • Novartis$559
  • Johnson & Johnson$249
  • Sun Pharmaceutical Industries Inc.$222
  • E.r. Squibb & Sons, L.L.C.$221
  • Regeneron Healthcare Solutions, Inc.$219
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,35489%
  • Education$42711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,780 in reported general payments places this provider in the 70th percentile of 52 dermatology providers in Idaho.

See all dermatology providers in Idaho

Medicare billing

Part B allowed, 2024
$342,750
Medicare patients
600
Services billed
3,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa21$470,225
Dupixent PenDupilumab21$78,895
Humira(Cf) PenAdalimumab12$77,753
OtezlaApremilast13$66,583
AdbryTralokinumab-Ldrm13$50,326
Calcipotriene26$8,020
Fluorouracil68$6,227
Tacrolimus30$5,698
Clobetasol Propionate144$5,170
Doxycycline Hyclate219$3,646
Desonide55$3,491
Mupirocin279$2,390
Ketoconazole148$2,324
Betamethasone Dipropionate54$2,187
Cephalexin246$1,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$92$66,58313 claims
LEO Pharma Inc.Adbry$198$50,32613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 52 dermatology providers in Idaho.

Other dermatology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →